ArticleDiscover oncology2026
Bioinformatics analysis and preliminary clinical validation of ITGA9 and NPTX2 as prognosis-related genes in acute myeloid leukemia.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression and clinical significance of integrin subunit alpha 9 (ITGA9) and neuronal pentraxin 2 (NPTX2) in acute myeloid leukemia (AML), and to evaluate their potential diagnostic and prognostic value.
methodsDifferentially expressed genes (DEGs) associated with AML prognosis were identified from the Gene Expression Omnibus (GEO) dataset (GSE12417), followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. The expression and prognostic relevance of candidate genes were further validated using The Cancer Genome Atlas (TCGA) dataset and the Xiantao Academic online platform. Correlations of ITGA9 and NPTX2 with immune-regulatory genes, immune checkpoint molecules, and immune cell infiltration were analyzed to explore their potential immune associations. Peripheral blood samples from 60 newly diagnosed AML patients and 50 healthy controls were collected for quantitative real-time PCR validation. Diagnostic and prognostic performances were assessed using receiver operating characteristic (ROC) curve and Kaplan-Meier survival analyses.
resultsSeven prognosis-related genes were identified, among which ITGA9 and NPTX2 were significantly upregulated in AML. ITGA9 and NPTX2 were predominantly involved in modulating signaling receptor functions and were primarily associated with the phosphatidylinositol 3-kinase-AKT (PI3K-Akt) signaling. Immune correlation analysis revealed that ITGA9 and NPTX2 were associated with multiple immune-regulatory and checkpoint molecules, indicating potential involvement in AML immune microenvironment modulation. Clinical validation confirmed that ITGA9 and NPTX2 were markedly overexpressed in the AML patients. ROC curve analysis demonstrated strong diagnostic efficacy for ITGA9 and NPTX2. Among the 60 AML patients followed up, 29 died, and the deceased group exhibited significantly higher ITGA9 and NPTX2 expression. High expression of ITGA9 and NPTX2 was associated with reduced relapse-free survival.
conclusionITGA9 and NPTX2 are significantly overexpressed in AML and are closely associated with poor prognosis. Their strong diagnostic performance suggests that these two genes may serve as potential biomarkers and therapeutic targets for AML.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.